Sylvain Godreuil Selected Research

Tuberculosis (Tuberculoses)

1/2022	QuantiFERON-TB Gold Plus Assay in Patients With Latent vs. Active Tuberculosis in a Low Incidence Setting: Level of IFN-γ, CD4/CD8 Responses, and Release of IL-2, IP-10, and MIG.
12/2020	Laboratory development of a simple stool sample processing method diagnosis of pediatric tuberculosis using Xpert Ultra.
1/2019	A Treatment-Decision Score for HIV-Infected Children With Suspected Tuberculosis.
1/2018	Optimized Lysis-Extraction Method Combined With IS6110-Amplification for Detection of Mycobacterium tuberculosis in Paucibacillary Sputum Specimens.
1/2016	High IFN-γ Release and Impaired Capacity of Multi-Cytokine Secretion in IGRA Supernatants Are Associated with Active Tuberculosis.
5/2013	[Advantages and drawbacks of expectoration decontamination methods for tuberculosis and anti-tuberculosis drug resistance diagnosis].

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Sylvain Godreuil Research Topics

Disease

7	Infections 12/2018 - 04/2009
6	Tuberculosis (Tuberculoses) 01/2022 - 05/2013
3	Neoplasms (Cancer) 01/2019 - 01/2017
1	Aseptic Meningitis 01/2022
1	Sexually Transmitted Diseases (Sexually Transmitted Disease) 01/2021
1	Pneumonia (Pneumonitis) 01/2021
1	Infertility (Sterility) 01/2020
1	Cystic Fibrosis (Mucoviscidosis) 03/2018
1	Latent Tuberculosis 01/2018
1	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 10/2017
1	Lung Neoplasms (Lung Cancer) 01/2017
1	Communicable Diseases (Infectious Diseases) 07/2014
1	Sacroiliitis 01/2014
1	Bacteremia 01/2014
1	Superinfection 03/2012
1	Pulmonary Tuberculosis 03/2012
1	Respiratory Distress Syndrome (Acute Respiratory Distress Syndrome) 03/2012
1	Infection with Mycobacterium marinum 11/2011
1	Burns 06/2011

Drug/Important Bio-Agent (IBA)

2	GoldIBA 01/2022 - 01/2019
2	CytokinesIBA 01/2022 - 01/2016
2	Anti-Bacterial Agents (Antibiotics)IBA 01/2021 - 01/2014
1	Interleukin-2 (IL2)IBA 01/2022
1	Polysaccharides (Glycans)IBA 01/2022
1	SteroidsIBA 01/2022
1	MacrolidesIBA 01/2021
1	Sucrose (Saccharose)IBA 12/2020
1	SuspensionsIBA 01/2020
1	AgarIBA 01/2020
1	Tyrosine Kinase InhibitorsIBA 01/2019
1	carbapenemaseIBA 12/2018
1	Amikacin (A.M.K)FDA LinkGeneric 03/2018
1	AntibodiesIBA 01/2018
1	copper tetra(4-N-methylpyridyl)porphineIBA 01/2018
1	AntigensIBA 01/2018
1	EnzymesIBA 01/2018
1	Nucleic AcidsIBA 01/2018
1	Anaplastic Lymphoma KinaseIBA 10/2017
1	Biomarkers (Surrogate Marker)IBA 01/2017
1	Circulating Tumor DNAIBA 01/2017
1	DNA (Deoxyribonucleic Acid)IBA 01/2017
1	Interferon-gamma (Interferon, gamma)IBA 01/2016
1	Biological ProductsIBA 07/2014
1	Antitubercular AgentsIBA 05/2013
1	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 11/2011
1	Local Anti-Infective Agents (Antiseptics)IBA 06/2011
1	Anti-Infective Agents (Microbicides)IBA 06/2011

Therapy/Procedure

2	Therapeutics 01/2017 - 04/2009
1	Catheters 01/2014
1	Artificial Respiration (Mechanical Ventilation) 03/2012